Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study

April 15, 2024

https://www.globenewswire.com/news-release/2024/04/15/2862602/0/en/Neumora-Therapeutics-Announces-Clinical-Hold-of-Phase-1-NMRA-266-Study.html

WATERTOWN, Mass., April 15, 2024 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced that the Phase 1 trial of NMRA-266 has been placed on clinical hold by the U.S. Food and Drug Administration (FDA). NMRA-266 is a positive allosteric modulator (PAM) of the M4 muscarinic receptor and is part of the Company’s M4 PAM franchise. The clinical hold determination follows recently available pre-clinical data showing convulsions in rabbits.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.